Antithymocyte immunoglobulin (rabbit)
- Generic Name
- Antithymocyte immunoglobulin (rabbit)
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 308067-60-9
- Unique Ingredient Identifier
- D7RD81HE4W
- Background
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
- Indication
For prevention of renal transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
- Conditions
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 32
- Registration Number
- NCT02627573
- Locations
- 🇷🇺
First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 17
- Registration Number
- NCT02582775
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States
A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 110
- Registration Number
- NCT02544113
- Locations
- 🇺🇸
Cleveland Clinic (Main Campus), Cleveland, Ohio, United States
🇺🇸University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
🇺🇸Cleveland Clinic Florida, Weston, Florida, United States
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2024-10-29
- Target Recruit Count
- 23
- Registration Number
- NCT02512497
- Locations
- 🇺🇸
The Ohio State University Cancer Center, Columbus, Ohio, United States
Minimal Islet Transplant at Diabetes Onset
- Conditions
- Interventions
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Ospedale San Raffaele
- Target Recruit Count
- 6
- Registration Number
- NCT02505893
- Locations
- 🇮🇹
IRCCS San Raffaele Scientific Institute, Milan, Italy
Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant
- Conditions
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT02464878
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Thymoglobulin Induction Therapy in Kidney Transplantation (6mg/kg vs 4mg/kg)
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 154
- Registration Number
- NCT02447822
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT02441803
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT02404025
- Locations
- 🇯🇵
Novartis Investigative Site, Tokyo, Japan
Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT02314403
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.